← Back to Search

Brachytherapy

HDR Brachytherapy for Prostate Cancer

N/A
Recruiting
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No TRUP within the past 6 months, nor large TURP defect
Age ≥ 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will investigate a new, more targeted form of radiation therapy for prostate cancer, which may result in fewer side effects and improved quality of life.

Who is the study for?
Men over 18 with early-stage, low to favorable intermediate-risk prostate cancer can join this study. They should be in good health (ECOG status 0-2), have a prostate size <80cc, and no history of severe rectal conditions or certain autoimmune diseases. No prior radiation or brachytherapy for the prostate is allowed, and they must not have any contraindications to MRI or anesthesia.
What is being tested?
The trial is testing two types of high dose rate (HDR) brachytherapy treatments for localized prostate cancer: one that targets the whole gland and another that focuses on specific areas identified by MRI. The goal is to see if focal treatment reduces side effects while maintaining effectiveness.
What are the potential side effects?
Potential side effects include urinary discomfort, incontinence, rectal symptoms like bleeding or pain, and sexual dysfunction such as erectile problems. These are common with traditional whole-gland treatments; the trial will assess if focal therapy lessens these issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I haven't had a prostate surgery or a large prostate tissue removal in the last 6 months.
Select...
I am 18 years old or older.
Select...
I am able to care for myself and perform daily activities.
Select...
My prostate cancer is confirmed by tissue analysis.
Select...
My prostate is smaller than 80cc.
Select...
I can safely undergo general or spinal/epidural anesthesia.
Select...
I don't have bleeding disorders and can stop blood thinners for brachytherapy.
Select...
I have never had Ulcerative Colitis, Crohn's Disease, Ataxia Telangiectasia, or Lupus.
Select...
I don't have severe hemorrhoids, recent colorectal surgery, or a missing rectum.
Select...
I have not had radiation therapy to my pelvis or prostate.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Tumour visible on MRIExperimental Treatment1 Intervention
Targeted focal HDR Brachytherapy to dominant lesion +/- whole-gland elective dose
Group II: No tumour visible on MRIActive Control1 Intervention
Whole-gland HDR Brachytherapy

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,524 Previous Clinical Trials
503,174 Total Patients Enrolled
65 Trials studying Prostate Cancer
15,562 Patients Enrolled for Prostate Cancer

Media Library

Targeted Focal HDR Brachytherapy (Brachytherapy) Clinical Trial Eligibility Overview. Trial Name: NCT02918253 — N/A
Prostate Cancer Research Study Groups: No tumour visible on MRI, Tumour visible on MRI
Prostate Cancer Clinical Trial 2023: Targeted Focal HDR Brachytherapy Highlights & Side Effects. Trial Name: NCT02918253 — N/A
Targeted Focal HDR Brachytherapy (Brachytherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02918253 — N/A
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top